Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pierre fabre italia s.p.a. - tazarotene - tazarotene

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/4897/2022 (h1n1)pdm09-like strain (a/norway/31694/2022, medi 369815)), virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like (a/norway/16606/2021 (medi 355293)), virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like: b/austria/1359417/2021 (medi 355293, victoria lineage)) - nasenspray, suspension - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/4897/2022 (h1n1)pdm09-like strain (a/norway/31694/2022, medi 369815)) 70 mio. ffu, virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like (a/norway/16606/2021 (medi 355293)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like: b/austria/1359417/2021 (medi 355293, victoria lineage)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/phuket/3073/2013-like: b/phuket/3073/2013 (medi 306444, yamagata lineage)) 70 mio. ffu, saccharum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, gelatina hydrolysata, arginini hydrochloridum, natrii hydrogenoglutamas monohydricus, aqua ad iniectabile q.s. ad suspensionem pro 0.2 ml. - aktive immunisierung gegen influenza für kinder und jugendliche im alter von 2-18 jahren - vaccini

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, umano - vaccini contro l'influenza, influenza, vivo attenuato - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l'uso di fluenz tetra dovrebbe essere basato su raccomandazioni ufficiali.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)), virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)), virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) - nasenspray, suspension - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)) 70 mio. ffu, virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/phuket/3073/2013-like: b/phuket/3073/2013 (medi 306444, yamagata lineage)) 70 mio. ffu, saccharum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, gelatina hydrolysata, arginini hydrochloridum, natrii hydrogenoglutamas monohydricus, aqua ad iniectabile q.s. ad suspensionem pro 0.2 ml. - aktive immunisierung gegen influenza für kinder und jugendliche im alter von 2-18 jahren - vaccini

Unione Europea - italiano - EMA (European Medicines Agency)

le vet b.v. - prednisolone - i corticosteroidi per uso sistemico, pianura, prednisolone, preparati ormonali sistemici, escl. ormoni sessuali e di insulina - cavalli - attenuazione dei parametri infiammatori e clinici associati all'ostruzione delle vie aeree ricorrenti (rao) nei cavalli, in combinazione con il controllo ambientale.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

maras ag - sitagliptinum - compresse rivestite con film - sitagliptinum 25 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, lactosum monohydricum 1.2 mg, hypromellosum, e 171, triacetinum, e 172 (rubrum), pro compresso obducto corresp. natrium 0.62 mg. - diabetes mellitus typ 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

maras ag - sitagliptinum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, poly(vinylis acetas), macrogolum 3350, e 171, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.25 mg. - diabetes mellitus typ 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

maras ag - sitagliptinum - compresse rivestite con film - sitagliptinum 100 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, poly(vinylis acetas), macrogolum 3350, e 171, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 2.5 mg. - diabetes mellitus typ 2 - synthetika

Italia - italiano - Ministero della Salute

koo medical equipment (shanghai) co., ltd. - maschere laringee monolume

Italia - italiano - Ministero della Salute

koo manufacturing, inc. - maschere laringee monolume